This page contains a Flash digital edition of a book.
APIs


commercial manufacturing. It combines Solvias’ expertise in chemical, analytical and solid-state development and RohnerChem’s experience in scale-up and commercial-scale custom synthesis of complex, small-molecule fine chemicals and APIs. The companies, located close to one another in the Basel area, have a long history of co-operation which has resulted in a number of successful projects, one of which was recognised with the European Outsourcing Award. Solvias applies high throughput screening methods (HTS) that have been used in asymmetric homogeneous catalysis, CX-couplings, racemate resolutions, carbonylations, hydroformylations, biocatalysis development, and various other transformations. In addition, the company’s solid-state development group is equipped to assist in developing crystallisation processes, perform polymorphism studies, and provide guidance in the development of the best solid form for any API. After process optimisation, which can be performed either at Solvias’ or at RohnerChem’s kilo lab, commercial quantities can be manufactured at RohnerChem’s FDA-inspected facilities. The companies say the co-operation will ensure consideration of scale-up requirements from early phases onwards, resulting in reduced overall timelines.


The companies will continue to exploit their expertise in enantioselective catalysis for the efficient production of building blocks and APIs, as well as expertise in catalytic, high- pressure, organometallic, cryogenic and various other synthesis technology areas.


CARBOGEN AMCIS and Polymun Scientific collaboration


In October, pharmaceutical process development services provider and API manufacturer CARBOGEN AMCIS signed a strategic alliance agreement with Polymun Scientific GmbH, an Austrian company specialised in liposomal formulations and biopharmaceuticals, giving CARBOGEN AMCIS access to Polymun’s innovative liposome technology for the formulation of APIs. Polymun receives access to CARBOGEN AMCIS’ expertise in the development and manufacture of highly potent APIs. The agreement enables Polymun to expand its service offerings to cytotoxics and cytostatics. “We believe that our customers are interested in finding new ways to better deliver highly potent active ingredients. This alliance expands our portfolio of offerings and moves us one step closer to achieving this goal,” said Mark Griffiths, CEO of CARBOGEN AMCIS. CARBOGEN AMCIS offers a range of drug


Solvias’ new ultra performance liquid chromatography laboratories in the company’s Römerpark facility located in Kaiseraugst, near Basel, Switzerland.


development and commercialisation services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The company is owned by India- headquartered Dishman Pharmaceuticals and Chemicals Ltd. Polymun Scientific Immunbiologische Forschung GmbH offers contract development and manufacturing services for biopharmaceuticals using both mammalian and microbial cell technology. In addition, the company offers its liposome technology for the formulation of pharmaceutically active ingredients and vaccine antigens.


University of Alberta chemical process licensed to GreenCentre


A ‘green’ chemical process with the potential to make production of pharmaceutical products more efficient and environmentally friendly has been licensed to GreenCentre Canada from the University of Alberta. The process, developed by UAlberta chemist Dr Dennis Hall, uses a novel, heavy-metal-free catalyst that can be used at room temperature without creating toxic by-products. The catalyst is used to create amide bonds, a common component of pharmaceutical compounds. Existing methods often require high temperatures and involve multiple steps and the addition of solvents or other toxic chemicals. GreenCentre will work with Hall to scale up the catalyst and use it to make compounds of pharmaceutical interest, as well as compounds of interest to the agricultural and plastics industries. Funded by the governments of Ontario and Canada, and by industry, GreenCentre Canada is dedicated to developing


environmentally friendly alternatives to traditional chemical and manufacturing products and practices. It is governed and operated with the assistance of industry members and is located at Innovation Park at Queen’s University in Kingston, Ontario.


Evonik expands HPAPI laboratory and production capacity


Evonik Industries AG has set up a new laboratory at its Hanau, Germany site for HPAPIs and expanded its cGMP capacity for HPAPIs at kilogram scale at Tippecanoe Laboratories in Lafayette, Indiana, USA. The new laboratory at Hanau now enables the company to develop and optimise syntheses for HPAPIs in Germany: The company already has similar laboratory facilities in the USA. With the expanded production capacity, Evonik now has a total reactor volume for HPAPIs of 170 cubic metres. Of this , about 135 cubic metres are used for production of HPAPIs at tonne scale, and about 35 cubic metres for smaller quantities.


Further information For further information on the companies and organisations featured in this article visit the following websites:


www.almacgroup.com www.c-mlabs.com www.safcglobal.com www.solvias.ch www.rohnerag.ch www.carbogen-amcis.com www.polymun.com www.ualberta.ca www.greencentrecanada.com www.evonik.com


November/December 2011 sp2 27


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44